OPKO Health, Inc.

OPK Healthcare Diagnostics & Research

OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.53 0.08 −4.97%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−4.7×
Dividend yield
—
F-score
4/9
Altman Z
−0.42
Beneish M
−2.81
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 79.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
5 2 4 2 7 5 1 3 3 4
P/S ratio
4.48 2.88 1.71 0.97 1.76 1.76 0.87 1.37 1.43 1.56
Altman Z-Score
4.57 1.67 1.05 (0.12) 1.78 2.75 (0.07) (0.07) (0.23) (0.42)
P/FCF ratio
1,021.88 0.00 0.00 0.00 0.00 50.11 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
2.68 0.65 0.87 (0.28) 0.79 1.82 (0.19) (1.08) (0.41) (0.79)
Beneish M-Score
(1.91) (3.04) (2.72) (2.94) (1.71) (2.63) (3.37) (2.97) (2.33) (2.81)
P/Operating CF
165.22 1,317.08 (48.91) (19.01) 73.87 (552.41) (27.74) (30.82) (22.97) (36.51)
P/B ratio
2.39 1.51 0.95 0.54 1.51 1.85 0.56 0.85 0.75 0.75
Price to Tangible BV
8.03 6.28 3.56 2.12 4.90 3.70 6.17 23.29 4.65 3.54
EV/Sales
4.38 2.82 1.71 1.12 1.89 1.79 0.97 1.54 1.43 1.51
EV/EBITDA
18,694.23 0.00 0.00 0.00 18.87 32.42 0.00 0.00 0.00 0.00
EV/Operating CF
152.72 (29.63) (15.51) (5.86) 68.81 83.08 (10.20) (47.03) (5.57) (5.15)
EV/FCF
998.81 (19.31) (11.62) (5.19) (685.78) 51.20 (7.60) (25.62) (4.68) (4.58)
Quick Ratio
1.48 0.82 0.83 0.88 0.95 1.20 1.31 1.10 2.85 3.13
Current Ratio
1.84 1.12 1.10 1.30 1.39 2.49 1.85 1.55 3.43 3.97
Net Debt/EBITDA
(431.49) 0.29 0.02 (0.76) 1.29 0.69 (0.81) (2.89) (0.04) 1.33
Debt/Assets
2.01% 1.59% 3.86% 9.56% 10.43% 8.44% 11.40% 12.01% 19.73% 17.69%
Debt/Equity
0.03 0.02 0.05 0.14 0.15 0.12 0.16 0.17 0.32 0.27
Asset Turnover
0.40 0.36 0.39 0.38 0.60 0.73 0.44 0.41 0.34 0.29
Operating CF/Net income
(0.66) 0.30 0.71 0.55 1.29 (1.27) 0.29 0.15 3.45 0.79
Capex/Depreciation
(0.23) (0.38) (0.27) (0.13) (0.39) 0.43 (0.21) (0.13) (0.25) (0.12)
Interest Coverage
(12.99) (41.88) (14.40) (12.74) 2.63 0.99 (18.77) (11.63) (3.20) (1.08)
ROE
(2.38%) (15.51%) (8.42%) (18.49%) 1.86% (1.80%) (20.23%) (12.80%) (3.86%) (17.14%)
ROA
(1.74%) (11.40%) (6.07%) (13.23%) 1.28% (1.24%) (14.38%) (9.04%) (2.53%) (10.92%)
ROIC
(3.05%) (9.64%) (5.98%) (9.79%) 1.94% 0.67% (8.54%) (6.39%) (6.95%) (5.91%)
Return on Tangible Assets
(14.09%) (166.45%) (87.91%) (155.87%) 10.61% (5.26%) (124.43%) (102.17%) (9.87%) (44.33%)
Average Days of Receivables
71.95 62.54 53.04 54.48 72.80 53.40 46.27 52.15 60.40 54.28
Research and Development Expense of Revenue
10.19% 13.09% 12.68% 13.07% 5.25% 4.33% 7.36% 10.38% 14.75% 20.44%
Selling, General and Administrative Expense of Revenue
36.45% 42.92% 36.19% 38.06% 24.77% 26.42% 37.11% 34.81% 42.66% 36.75%
Intangible Assets out of Total Assets
0.53 0.54 0.54 0.52 0.47 0.35 0.65 0.67 0.52 0.52
Share Based Compensation of Revenue
3.82% 2.93% 2.20% 1.49% 0.62% 0.77% 1.84% 1.32% 1.55% 1.77%
Graham Net Nets
(0.04) (0.14) (0.20) (0.42) (0.11) 0.03 (0.24) (0.27) (0.17) (0.09)
Graham Number
0.00 0.00 0.00 0.00 1.71 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(0.96%) (11.07%) (8.97%) (36.05%) 1.27% (1.04%) (36.07%) (15.92%) (5.09%) (23.81%)
Free Cash Flow Yield
0.10% (5.09%) (8.60%) (22.23%) (0.16%) 2.00% (14.57%) (4.39%) (21.39%) (21.19%)
Revenue per Share
2.03 1.73 1.76 1.51 2.24 2.74 1.40 1.15 1.03 0.81
Operating CF per Share
0.06 (0.16) (0.19) (0.29) 0.06 0.06 (0.13) (0.04) (0.26) (0.24)
Capex per Share
(0.04) (0.07) (0.05) (0.02) (0.05) 0.05 (0.03) (0.02) (0.04) (0.02)
Free Cash Flow per Share
0.02 (0.23) (0.24) (0.31) 0.01 0.11 (0.16) (0.06) (0.30) (0.25)
Cash per Share
0.31 0.16 0.17 0.14 0.11 0.21 0.21 0.13 0.62 0.49
Shareholders Equity per Share
3.80 3.30 3.18 2.71 2.61 2.60 2.17 1.85 1.97 1.69
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
3.80 3.30 3.18 2.71 2.61 2.60 2.17 1.85 1.97 1.69
Free Cash Flow
9.90 (131.33) (135.78) (184.59) 6.04 72.21 (117.82) (41.76) (208.26) (190.53)
Working Capital
220.31 36.83 29.41 74.93 147.70 493.01 181.05 109.42 468.99 435.20
Capital Expenditures
(22.15) (39.25) (26.63) (12.07) (33.44) 33.87 (22.63) (13.56) (24.77) (11.99)
Net Current Asset Value
(191.21) (397.47) (342.05) (370.47) (278.33) 108.42 (211.09) (313.00) (172.67) (82.10)
EV/EBIT
0.00 0.00 0.00 0.00 47.07 169.88 0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.04 0.03 0.01 0.02 (0.02) 0.02 0.02 0.03 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 43.85 166.25 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.79 0.70 0.67 0.75 0.61 1.00 1.33 1.41 1.43 1.31
Cash ROIC
0.43% (6.65%) (6.85%) (9.61%) 0.30% 3.57% (6.01%) (2.42%) (9.33%) (9.63%)
Accounts Receivable Turnover
5.40 5.01 6.40 6.48 6.82 6.50 5.19 6.89 5.91 5.83
Accounts Payable Turnover
9.71 9.71 9.94 10.42 4.42 5.63 9.61 7.98 8.47 9.09
Inventory Turnover
14.07 12.84 13.20 11.96 9.63 10.90 8.92 7.80 8.08 6.54
Average Days of Payables
31.85 43.74 28.61 39.87 139.47 25.10 34.15 46.63 34.73 37.42
Days of Inventory on Hand
28.19 29.04 25.53 34.07 54.01 26.46 37.76 43.97 41.91 59.92
Average Receivables
207.08 192.90 154.71 139.26 210.47 272.98 193.47 125.35 120.70 104.14
Average Payables
62.95 63.83 60.85 54.97 202.14 211.90 74.52 68.34 58.37 44.09
Average Inventory
43.45 48.28 45.82 47.87 92.89 109.42 80.28 69.88 61.25 61.31
Average Assets
2,782.90 2,678.29 2,520.51 2,380.17 2,391.17 2,436.39 2,283.49 2,089.48 2,105.96 2,066.08
Average Common Equity
2,035.80 1,967.72 1,817.46 1,703.03 1,643.16 1,678.34 1,623.39 1,475.43 1,377.33 1,316.70

Fold the line items

Columns are period end dates